A4250, an IBAT Inhibitor in Pediatric Cholestasis (NCT02630875) | Clinical Trial Compass
CompletedPhase 2
A4250, an IBAT Inhibitor in Pediatric Cholestasis
Denmark, France, Germany24 participantsStarted 2015-08
Plain-language summary
This study will evaluate A4250 (IBATinhibitor) as a treatment option in pediatric patients with chronic cholestasis with main emphasis on safety evaluation and on effects on pruritus
Who can participate
Age range1 Year – 18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosis of pruritus due to chronic cholestasis based on history and investigator judgment. This will include but will not be restricted to patients with Progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS), Biliary Atresia and Sclerosing Cholangitis
Exclusion Criteria:
* Any condition that in the opinion of the investigator constitutes a risk for the patient or a contraindication for participation and completion of the study, or could interfere with study objectives, conduct, or evaluations
* Clinical or biochemical signs of decompensated liver disease
* Liver transplantation